{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:56:51Z","timestamp":1779357411857,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13300-019-00744-6","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T16:03:27Z","timestamp":1576857807000},"page":"423-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Multinational Real-World Study on the Clinical Characteristics of Patients with Type\u00a02 Diabetes Initiating Dapagliflozin in Southern Europe"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Tentolouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Caballero Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Bellido Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crist\u00f3bal","family":"Morales Portillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"744_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"K Ogurtsova","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40\u201350.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"744_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jchf.2016.08.001","volume":"4","author":"FS Ahmad","year":"2016","unstructured":"Ahmad FS, Ning H, Rich JD, et al. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart Fail. 2016;4(12):911\u20139.","journal-title":"JACC Heart Fail"},{"issue":"7","key":"744_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.298.7.765","volume":"298","author":"SM Donahoe","year":"2007","unstructured":"Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298(7):765\u201375.","journal-title":"JAMA"},{"issue":"15","key":"744_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1056\/NEJM199910073411506","volume":"341","author":"E Ritz","year":"1999","unstructured":"Ritz E, Orth SR. Nephropathy in patients with type\u00a02 diabetes mellitus. N Engl J Med. 1999;341(15):1127\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"744_CR5","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics\u20132011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18\u2013209.","journal-title":"Circulation"},{"issue":"12","key":"744_CR6","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, Dalessio DA, Fradkin J, et al. Management of hyperglycemia in type\u00a02 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"6","key":"744_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723\u20139.","journal-title":"Diabetes"},{"issue":"5","key":"744_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2\u00a0weeks in patients with type\u00a02 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"744_CR9","unstructured":"Dapagliflozin. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forxiga-epar-product-information_it.pdf. Accessed 17 Dec 2019."},{"issue":"4","key":"744_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323\u201334.","journal-title":"Circulation"},{"issue":"7","key":"744_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"744_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"11","key":"744_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMc1600140","volume":"374","author":"B Zinman","year":"2016","unstructured":"Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2016;374(11):1094.","journal-title":"N Engl J Med"},{"issue":"4","key":"744_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"key":"744_CR15","doi-asserted-by":"crossref","unstructured":"Hupfeld C, Mudaliar S. Navigating the \u201cMACE\u201d in cardiovascular outcomes trials and decoding the relevance of atherosclerotic cardiovascular disease benefits versus heart failure benefits. Diabetes Obes Metab. 2019;21(8):1780\u20139.","DOI":"10.1111\/dom.13740"},{"key":"744_CR16","doi-asserted-by":"publisher","first-page":"107726","DOI":"10.1016\/j.diabres.2019.05.005","volume":"159","author":"Andr\u00e9 J. Scheen","year":"2020","unstructured":"Scheen AJ. Implications of the recent CVOTs in type\u00a02 diabetes: impact on guidelines: the endocrinologist point of view. Diabetes Res Clin Pract. 2019. https:\/\/doi.org\/10.1016\/j.diabres.2019.05.005.","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"5","key":"744_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMra1614394","volume":"377","author":"TR Frieden","year":"2017","unstructured":"Frieden TR. Evidence for health decision making\u2014beyond randomized, controlled trials. N Engl J Med. 2017;377(5):465\u201375.","journal-title":"N Engl J Med"},{"issue":"3","key":"744_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"5","key":"744_CR19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1210\/jc.2016-3446","volume":"102","author":"KA Toulis","year":"2017","unstructured":"Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the Health Improvement Network database. J Clin Endocrinol Metab. 2017;102(5):1719\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"744_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/dom.12889","volume":"19","author":"T Nystrom","year":"2017","unstructured":"Nystrom T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type\u00a02 diabetes. Diabetes Obes Metab. 2017;19(6):831\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"744_CR21","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dom.13627","volume":"21","author":"A Norhammar","year":"2019","unstructured":"Norhammar A, Bodegard J, Nystrom T, et al. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type\u00a02 diabetes similar to that of the DECLARE-TIMI\u00a058 trial: a nationwide observational study. Diabetes Obes Metab. 2019;21(5):1136\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"744_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/CRD.0000000000000201","volume":"26","author":"R Dalan","year":"2018","unstructured":"Dalan R. Sodium-glucose cotransporter-2 inhibition in type\u00a02 diabetes mellitus: a review of large-scale cardiovascular outcome studies and possible mechanisms of benefit. Cardiol Rev. 2018;26(6):312\u201320.","journal-title":"Cardiol Rev"},{"issue":"12","key":"744_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.numecd.2017.08.001","volume":"27","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Zatti G, Consoli A, et al. Rationale and design of the DARWIN-T2D (dapagliflozin real world evidence in type\u00a02 diabetes): a multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017;27(12):1089\u201397.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"744_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.13747","volume":"21","author":"GP Fadini","year":"2019","unstructured":"Fadini GP, Sciannameo V, Franzetti I, et al. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: a multicentre retrospective study. Diabetes Obes Metab. 2019;21:1886\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"744_CR25","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/dom.13738","volume":"21","author":"E Wittbrodt","year":"2019","unstructured":"Wittbrodt E, Chamberlain D, Arnold SV, et al. Eligibility of patients with type\u00a02 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: an assessment using the diabetes collaborative registry. Diabetes Obes Metab. 2019;21:1985\u20139.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-00744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-019-00744-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-00744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:11:02Z","timestamp":1724411462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-019-00744-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s13300-019-00744-6","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"10 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}